Nuclear targeting Subcellular-delivery nanosystems for precise cancer treatment
Copyright © 2022 Elsevier B.V. All rights reserved..
With the exponential growth of nanomedicine research, subcellular-delivery nanosystems (SDNSs) has rapidly become a research focus, which suggests that the idea of curing cancer may not be a pipe dream. As the center of genetic material storage, replication, and transcription, the nucleus can be regarded as the final target of many cancer treatment methods. Thus, nuclear-targeted SDNSs may have clinical potential for precise cancer treatment by delivering therapeutic agents and assisting various treatment methods. Herein, the latest progress of nuclear-targeted SDNSs for cancer treatment are reviewed and listed. Additionally, the possible mechanisms of SDNSs entering the nucleus and its applications in the field of cancer treatment as well as some typical preparations are summarized and the exciting future of SDNSs is also briefly highlighted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:619 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 619(2022) vom: 10. Mai, Seite 121735 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Du, Wenzhen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 28.04.2022 Date Revised 28.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2022.121735 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339348860 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339348860 | ||
| 003 | DE-627 | ||
| 005 | 20231226002712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2022.121735 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339348860 | ||
| 035 | |a (NLM)35405280 | ||
| 035 | |a (PII)S0378-5173(22)00290-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Du, Wenzhen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nuclear targeting Subcellular-delivery nanosystems for precise cancer treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2022 | ||
| 500 | |a Date Revised 28.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a With the exponential growth of nanomedicine research, subcellular-delivery nanosystems (SDNSs) has rapidly become a research focus, which suggests that the idea of curing cancer may not be a pipe dream. As the center of genetic material storage, replication, and transcription, the nucleus can be regarded as the final target of many cancer treatment methods. Thus, nuclear-targeted SDNSs may have clinical potential for precise cancer treatment by delivering therapeutic agents and assisting various treatment methods. Herein, the latest progress of nuclear-targeted SDNSs for cancer treatment are reviewed and listed. Additionally, the possible mechanisms of SDNSs entering the nucleus and its applications in the field of cancer treatment as well as some typical preparations are summarized and the exciting future of SDNSs is also briefly highlighted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Mechanisms | |
| 650 | 4 | |a Nano-delivery system | |
| 650 | 4 | |a Nuclear target | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Zhang, Lijing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaodan |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Guixia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 619(2022) vom: 10. Mai, Seite 121735 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:619 |g year:2022 |g day:10 |g month:05 |g pages:121735 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2022.121735 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 619 |j 2022 |b 10 |c 05 |h 121735 | ||